SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-20-000006
Filing Date
2020-05-22
Accepted
2020-05-22 07:16:37
Documents
62
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20200331.htm   iXBRL 10-Q 1782198
2 EX-31.1 exhibit311.htm EX-31.1 20577
3 EX-31.2 exhibit312.htm EX-31.2 20418
4 EX-32.1 exhibit321.htm EX-32.1 13500
  Complete submission text file 0001664710-20-000006.txt   6115947

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20200331.xsd EX-101.SCH 32431
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20200331_cal.xml EX-101.CAL 59884
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20200331_def.xml EX-101.DEF 193903
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20200331_lab.xml EX-101.LAB 425694
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20200331_pre.xml EX-101.PRE 309184
43 EXTRACTED XBRL INSTANCE DOCUMENT kros-20200331_htm.xml XML 891566
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 20903620
SIC: 2834 Pharmaceutical Preparations